From the March Company Quarter report.
The Company understands the high level of interest of shareholders in the outcomes of the completed clinical trials. Trials such as BIT225-011 that include longitudinal analyses of a multitude of immunological markers involve complex, time-consuming modeling and consultation with relevant experts. Good progress is being made and the Company looks forward to reporting results during the second quarter of 2024.
We are past half way through the second quarter, so not long now.
From the March Company Quarter report.The Company understands...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.003(5.45%) |
Mkt cap ! $46.91M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.6¢ | 5.2¢ | $63.28K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12058 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 33995 | 1 |
View Market Depth
| Last trade - 15.51pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
-0.003 ( 5.45 %) |
||||
| Open | High | Low | Volume | ||
| 5.4¢ | 5.5¢ | 5.2¢ | 64903 | ||
| Last updated 15.35pm 07/06/2024 ? | |||||
| BIT (ASX) Chart |